A Multi-Model Machine Learning Framework for Identifying Raloxifene as a Novel RNA Polymerase Inhibitor from FDA-Approved Drugs.

RNA-dependent RNA polymerase (RdRP) represents a critical target for antiviral drug development. We developed a multi-model machine learning framework combining five traditional algorithms (ExtraTreesClassifier, RandomForestClassifier, LGBMClassifier, BernoulliNB, and BaggingClassifier) with a CNN deep learning model to identify potential RdRP inhibitors among FDA-approved drugs. Using the PubChem dataset AID 588519, our ensemble models achieved the highest performance with accuracy, ROC-AUC, and F1 scores higher than 0.70, while the CNN model demonstrated complementary predictive value with a specificity of 0.77 on external validation. Molecular docking studies with the norovirus RdRP (PDB: 4NRT) identified raloxifene as a promising candidate, with a binding affinity (-8.8 kcal/mol) comparable to the positive control (-9.2 kcal/mol). The molecular dynamics simulation confirmed stable binding with RMSD values of 0.12-0.15 nm for the protein-ligand complex and consistent hydrogen bonding patterns. Our findings suggest that raloxifene may possess RdRP inhibitory activity, providing a foundation for its experimental validation as a potential broad-spectrum antiviral agent.